Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Taysha Gene Therapies, Inc. before investing.

In this article, we go over a few key elements for understanding Taysha Gene Therapies, Inc.’s stock price such as:

• Taysha Gene Therapies, Inc.’s current stock price and volume
• Why Taysha Gene Therapies, Inc.’s stock price changed recently
• Upgrades and downgrades for TSHA from analysts
• TSHA’s stock price momentum as measured by its relative strength

About Taysha Gene Therapies, Inc. (TSHA)

Before we jump into Taysha Gene Therapies, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Want to learn more about Taysha Gene Therapies, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Taysha Gene Therapies, Inc..

Taysha Gene Therapies, Inc.’s Stock Price as of Market Close

As of August 21, 2026, 4:00 PM, CST, Taysha Gene Therapies, Inc.’s stock price was $6.090.

Taysha Gene Therapies, Inc. is down 0.33% from its previous closing price of $6.110.

During the last market session, Taysha Gene Therapies, Inc.’s stock traded between $6.015 and $6.240. Currently, there are approximately 369.04 million shares outstanding for Taysha Gene Therapies, Inc..

Taysha Gene Therapies, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Taysha Gene Therapies, Inc. Stock Price History

Taysha Gene Therapies, Inc.’s (TSHA) price is currently up 3.92% so far this month.

During the month of August, Taysha Gene Therapies, Inc.’s stock price has reached a high of $6.750 and a low of $5.630.

Over the last year, Taysha Gene Therapies, Inc. has hit prices as high as $7.300 and as low as $2.711. Year to date, Taysha Gene Therapies, Inc.’s stock is up 10.73%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Taysha Gene Therapies, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 20, 2026, there were 2 analysts who downgraded Taysha Gene Therapies, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Taysha Gene Therapies, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Taysha Gene Therapies, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Taysha Gene Therapies, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Taysha Gene Therapies, Inc. (TSHA) by visiting AAII Stock Evaluator.

Relative Price Strength of Taysha Gene Therapies, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 20, 2026, Taysha Gene Therapies, Inc. has a weighted four-quarter relative price strength of 14.49%, which translates to a Momentum Score of 87 and is considered to be Very Strong.

Want to learn more about how Taysha Gene Therapies, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Taysha Gene Therapies, Inc. Stock Price: Bottom Line

As of August 21, 2026, Taysha Gene Therapies, Inc.’s stock price is $6.090, which is down 0.33% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Taysha Gene Therapies, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.